

Highlights of This Issue 2483

SPECIAL FEATURES

Editorial

- 2485 | **Fighting Cancer Gets Personal**
Jesse Potash and Kenneth C. Anderson

CCR Translations

- 2486 | **Imaging Breast Cancer
Chemotherapy Response with Light**
Bruce J. Tromberg and Albert E. Cerussi
See article p. 2605

CCR New Strategies

- 2489 | **New Strategies in Head and Neck
Cancer: Understanding Resistance
to Epidermal Growth Factor
Receptor Inhibitors**
Lucy F. Chen, Ezra E.W. Cohen,
and Jennifer R. Grandis

CCR Drug Updates

- 2496 | **Maintenance Therapy for Advanced
Non-small Cell Lung Cancer:
Current Status, Controversies,
and Emerging Consensus**
Taofeek K. Owonikoko,
Suresh S. Ramalingam,
and Chandra P. Belani

Molecular Pathways

- 2505 | **Crosstalk between Insulin/Insulin-
like Growth Factor-1 Receptors
and G Protein-Coupled Receptor
Signaling Systems: A Novel Target
for the Antidiabetic Drug
Metformin in Pancreatic Cancer**
Enrique Rozengurt, James Sinnott-Smith,
and Krisztina Kisfalvi
- 2512 | **Targeting the Insulin-like Growth
Factor Receptor-1R Pathway for
Cancer Therapy**
Jiping Zha and Mark R. Lackner

HUMAN CANCER BIOLOGY

- 2518 | **Combined Functional Genome
Survey of Therapeutic Targets for
Hepatocellular Carcinoma**
Reiko Satow, Miki Shitashige, Yae Kanai,
Fumitaka Takeshita, Hidenori Ojima,
Takafumi Jigami, Kazufumi Honda,
Tomoo Kosuge, Takahiro Ochiya,
Setsuo Hirohashi, and Tesshi Yamada
- 2529 | **Differential Functions of Growth
Factor Receptor-Bound Protein 7
(GRB7) and Its Variant GRB7v in
Ovarian Carcinogenesis**
Yajun Wang, David W. Chan,
Vincent W.S. Liu, PM Chiu,
and Hextan Y.S. Ngan

CANCER THERAPY: PRECLINICAL

- 2540 | **Targeted Chemotherapy for Head
and Neck Cancer with a Chimeric
Oncolytic Adenovirus Coding for
Bifunctional Suicide Protein FCU1**
João D. Dias, Ilkka Liikanen, Kilian Guse,
Johann Foloppe, Marta Sloniecka,
Iulia Diaconu, Ville Rantanen,
Minna Eriksson, Tanja Hakkarainen,
Monika Lusky, Philippe Erbs,
Sophie Escutenaire, Anna Kanerva,
Sari Pesonen, Vincenzo Cerullo,
and Akseli Hemminki
- 2550 | **Inhibition of p-STAT3 Enhances
IFN- α Efficacy against Metastatic
Melanoma in a Murine Model**
Ling-Yuan Kong, Alexander Gelbard,
Jun Wei, Chantal Reina-Ortiz, Yongtao Wang,
Eric C. Yang, Yared Hailemichael,
Izabela Fokt, Arumugam Jayakumar,
Wei Qiao, Gregory N. Fuller,
Willem W. Overwijk, Waldemar Priebe,
and Amy B. Heimberger
- 2562 | **EphA2 Targeted Chemotherapy
Using an Antibody Drug Conjugate
in Endometrial Carcinoma**
Jeong-Won Lee, Rebecca L. Stone,
Sun Joo Lee, Eun Ji Nam, Ju-Won Roh,
Alpa M. Nick, Hee-Dong Han,
Mian M.K. Shahzad, Hye-Sun Kim,
Lingegowda S. Mangala, Nicholas B. Jennings,
Shenlan Mao, John Gooya, Dowdy Jackson,
Robert L. Coleman, and Anil K. Sood

2571 **Honokiol Inhibits Epidermal Growth Factor Receptor Signaling and Enhances the Antitumor Effects of Epidermal Growth Factor Receptor Inhibitors**

Rebecca J. Leeman-Neill, Quan Cai, Sonali C. Joyce, Sufi M. Thomas, Neil E. Bhola, Daniel B. Neill, Jack L. Arbiser, and Jennifer R. Grandis

2580 **Sulforaphane, a Dietary Component of Broccoli/Broccoli Sprouts, Inhibits Breast Cancer Stem Cells**

Yanyan Li, Tao Zhang, Hasan Korkaya, Suling Liu, Hsiu-Fang Lee, Bryan Newman, Yanke Yu, Shawn G. Clouthier, Steven J. Schwartz, Max S. Wicha, and Duxin Sun

2591 **TRAIL and Doxorubicin Combination Induces Proapoptotic and Antiangiogenic Effects in Soft Tissue Sarcoma *In vivo***

Suizhao Wang, Wenhong Ren, Jeffery Liu, Guy Lahat, Keila Torres, Gonzalo Lopez, Alexander J. Lazar, Andrea Hayes-Jordan, Kebin Liu, Jim Bankson, John D. Hazle, and Dina Lev

IMAGING, DIAGNOSIS, PROGNOSIS

2605 **Functional Imaging Using Diffuse Optical Spectroscopy of Neoadjuvant Chemotherapy Response in Women with Locally Advanced Breast Cancer**

Hany Soliman, Anoma Gunasekara, Mary Rycroft, Judit Zubovits, Rebecca Dent, Jacqueline Spayne, Martin J. Yaffe, and Gregory J. Czarnota

2615 **Signal Transducers and Activators of Transcription 5a-Dependent Cross-talk between Follicular Lymphoma Cells and Tumor Microenvironment Characterizes a Group of Patients with Improved Outcome after R-CHOP**

Minna Taskinen, Erkka Valo, Marja-Liisa Karjalainen-Lindsberg, Sampsa Hautaniemi, Seppo Meri, and Sirpa Leppä

2624 **Gene Expression Signature in Urine for Diagnosing and Assessing Aggressiveness of Bladder Urothelial Carcinoma**

Lourdes Mengual, Moisés Burset, María José Ribal, Elisabet Ars, Mercedes Marín-Aguilera, Manuel Fernández, Mercedes Ingelmo-Torres, Humberto Villavicencio, and Antonio Alcaraz

2634 **Detection and HER2 Expression of Circulating Tumor Cells: Prospective Monitoring in Breast Cancer Patients Treated in the Neoadjuvant GeparQuattro Trial**

Sabine Riethdorf, Volkmar Müller, Liling Zhang, Thomas Rau, Sibylle Loibl, Martina Komor, Marc Roller, Jens Huober, Tanja Fehm, Iris Schrader, Jörn Hilfrich, Frank Holms, Hans Tesch, Holger Eidtmann, Michael Untch, Gunter von Minckwitz, and Klaus Pantel

CANCER THERAPY: CLINICAL

2646 **Clinical Responses in a Phase II Study Using Adoptive Transfer of Short-term Cultured Tumor Infiltration Lymphocytes in Metastatic Melanoma Patients**

Michal J. Besser, Ronnie Shapira-Frommer, Avraham J. Treves, Dov Zippel, Orit Itzhaki, Liat Hershkovitz, Daphna Levy, Adva Kubi, Einat Hovav, Natalia Chermoshniuk, Bruria Shalmon, Izhar Hardan, Raphael Catane, Gal Markel, Sara Apter, Alon Ben-Nun, Iryna Kuchuk, Avichai Shimoni, Arnon Nagler, and Jacob Schachter

2656 **Phase I and Pharmacokinetic Study of Sequential Paclitaxel and Trabectedin Every 2 Weeks in Patients with Advanced Solid Tumors**

Quincy Chu, Alain Mita, Bahram Forouzes, Anthony W. Tolcher, Gary Schwartz, Antonio Nieto, Arturo Soto-Matos, Vicente Alfaro, Claudia Lebedinsky, and Eric K. Rowinsky

2666 **Pharmacokinetic Analysis and Phase 1 Study of MRX-1024 in Patients Treated with Radiation Therapy with or without Cisplatin for Head and Neck Cancer**

Daniel A. Hamstra, Avraham Eisbruch, Maddireddy U.R. Naidu, Gogula V. Ramana, Prasad Sunkara, Kathleen C.M. Campbell, Brian D. Ross, and Alnawaz Rehemtulla

2677 **A Phase Ib Study of AMG 102 in Combination with Bevacizumab or Motesanib in Patients with Advanced Solid Tumors**

Peter J. Rosen, Christopher J. Sweeney, Dorothy J. Park, Darrin M. Beaupre, Hongjie Deng, Ian M. Leitch, Poornima Shubhakar, Min Zhu, Kelly S. Oliner, Abraham Anderson, and Lorrin K. Yee

Clinical Benefit of Lapatinib-Based Therapy in Patients with Human Epidermal Growth Factor Receptor 2-Positive Breast Tumors Coexpressing the Truncated p95HER2 Receptor

Maurizio Scaltriti, Sarat Chandarlapaty, Ludmila Prudkin, Claudia Aura, José Jimenez, Pier Davide Angelini, Gertrudis Sánchez, Marta Guzman, Josep Lluís Parra, Catherine Ellis, Robert Gagnon, Maria Koehler, Henry Gomez, Charles Geyer, David Cameron, Joaquin Arribas, Neal Rosen, and José Baselga


CORRECTIONS

2696 **Correction: Development of Molecularly Targeted Therapies in Hepatocellular Carcinoma: Where Do We Go Now?**

2696 **Correction: Gene Expression Profiling for Discovery of Novel Markers of Minimal Disease**

ABOUT THE COVER

Low-dose doxorubicin and TRAIL combination results in enhanced CXCL10 expression in a leiomyosarcoma xenograft model as observed by immunofluorescent staining (cover image: CXCL10, red; nuclei, blue). Overexpression of this anti-angiogenic cytokine can contribute potentially, at least in part, to the significant reduction in tumor-associated vasculature associated with this therapeutic regimen. For details, see the article by Wang and colleagues on page 2591 of this issue.



Clinical Cancer Research

16 (9)

Clin Cancer Res 2010;16:2483-2696.

Updated version Access the most recent version of this article at:
<http://clincancerres.aacrjournals.org/content/16/9>

E-mail alerts [Sign up to receive free email-alerts](#) related to this article or journal.

Reprints and Subscriptions To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions To request permission to re-use all or part of this article, use this link <http://clincancerres.aacrjournals.org/content/16/9>. Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.